samedan logo
 
 
spacer
home > white papers > eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials - Clinical Ink
WHITE PAPERS

Clinical Ink

phone 1-800-301-5033
email info@clinicalink.com
web http://www.clinicalink.com
email 525 Vine Street, Suite 130, Winston-Salem, NC 27101

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

More sponsors and CROs are looking for new ways to better leverage investigative site relationships to improve clinical trial performance. To this end, some clinical organizations have adopted electronic source (eSource) to help improve study quality and efficiency - for both sponsor and site. Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. As SureSource adoption increased, study teams began to see an improvement in data quality, operational efficiency and ease of use compared to traditional methods (paper and EDC). A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution

October 5th, 2021 – SCHLIEREN, (Zurich, Switzerland). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.
More info >>


White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement